Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Cara Therapeutics vs. Intellia Therapeutics

By Keith Speights - Jun 16, 2019 at 9:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two biotechs that don't have approved drugs yet. One clear winner.

For most of 2019, Cara Therapeutics (CARA 6.18%) and Intellia Therapeutics (NTLA 5.16%) claimed very similar market caps. The two biotechs repeatedly swapped positions for the larger market cap. But thanks to encouraging phase 3 results for its lead drug, Korsuva, Cara is now valued at nearly $150 million more than Intellia.

Market caps don't matter much when it comes to picking the better stock to own over the long run, though. Which of these two biotechs has stronger prospects? Here's how Cara and Intellia compare against each other.

Three people in lab coats in a lab.

Image source: Getty Images.

The case for Cara Therapeutics

Cara Therapeutics doesn't have a product on the market yet, but it's getting pretty close to potentially reaching that milestone. The company announced results on May 29 from the Kalm-1 phase 3 study evaluating Korsuva injection in treating hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). And those results looked great.

Korsuva blew away the primary endpoint of the study -- statistically significant improvement in itching for patients on a numerical rating scale (NRS) measuring worst itching levels. The kappa opioid receptor (KOR) agonist also proved to be well-tolerated by patients through 12 weeks of treatment.

Cara now awaits the results of another late-stage study evaluating Korsuva injection in CKD-aP patients on hemodialysis. Those results are expected to be announced later in 2019. If they're as positive as the Kalm-1 results, Cara should move forward quickly with filing for FDA approval of its lead candidate.

The biotech already has a big partner lined up to market Korsuva, assuming it wins approval. A joint venture started by Fresenius Medical Care and Vifor Pharma Group will market the drug outside of the U.S., Japan, and South Korea. In addition, Fresenius is going to promote Korsuva in its U.S. dialysis centers.

Cara could have even bigger opportunities. The company should report results later this year from a phase 2 clinical study evaluating an oral version of Korsuva in treating CKD-aP patients who aren't on dialysis. It's also starting phase 2 studies of oral Korsuva in treating atopic dermatitis and chronic liver disease-associated pruritis (CLD-aP).

The case for Intellia Therapeutics

Intellia Therapeutics focuses on developing CRISPR gene editing therapies. The biotech has attracted the interest of two large partners, Novartis and Regeneron.

It's still really early for Intellia's gene editing program. The company doesn't expect to file for the FDA's blessing to begin its first clinical study of lead candidate NTLA-2001 until next year. That program will use CRISPR/Cas9 to target treatment of rare genetic disease transthyretin amyloidosis (ATTR).

Preclinical studies of NTLA-2001 in ATTR were promising. The therapy reduced the circulating TTR protein, which builds up deposits and causes ATTR, by an average of more than 95% in nonhuman primates. Regeneron is collaborating with Intellia on the development of NTLA-2001.

Intellia also expects to pick a candidate by the end of 2019 for targeting acute myeloid leukemia (AML). The biotech is using CRISPR gene editing to modify immune cells in the blood known as T cells so that they'll attack leukemic blasts that express Wilms' tumor 1 (WT1) epitopes (the part of the cancer cells that can bind to an antibody).

In addition, Intellia has made progress in preclinical testing of a gene editing therapy targeting the treatment of hemophilia B. This is another program with which the company is partnering with Regeneron.

Better buy

There's certainly a pretty good argument to make that Intellia could have more far-reaching therapies over the long run. That's why the biotech claims a market cap of more than $650 million even though it's years away from even the possibility of having an approved drug on the market.

However, Cara Therapeutics appears to be the better choice right now, in my opinion. The company should have a great chance at winning FDA approval for Korsuva injection in treating CKD-aP patients on hemodialysis. And if oral Korsuva proves to be effective as well, Cara will be worth a lot more than it is today. There are still risks for this biotech stock, but I think that Cara ranks as one of the more attractive small-cap stocks on the market right now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cara Therapeutics, Inc. Stock Quote
Cara Therapeutics, Inc.
CARA
$8.94 (6.18%) $0.52
Intellia Therapeutics Stock Quote
Intellia Therapeutics
NTLA
$48.33 (5.16%) $2.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.